USFDA warning letter on Lupin#39;s Somerset facility cites repeated GMP violations at Lupin#39;s manufacturing network

USFDA warning letter on Lupin#39;s Somerset facility cites repeated GMP violations at Lupin#39;s manufacturing network "Repeated violations at multiple sites demonstrate that your company’s corporate oversight and control over the manufacture of drugs is inadequate," USFDA said in its warning letter addressed to Vinita Gupta, CEO of Lupin.

from Moneycontrol Business News https://ift.tt/3x6aK4p
Posted by: at
Tags:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Start-up Street: Social justice and the start-up ecosystem

Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...